********************Oral PCSK9 inhibitor enlicitide cuts LDL 56-60% in phase 3 trials atop statins********************
Key Questions
What were the results of the CORALreef AddOn phase 3 trial for enlicitide?
Enlicitide, an oral PCSK9 inhibitor, reduced LDL by 65%, achieved 81% <70 mg/dL and 78% <55 mg/dL, and lowered Lp(a) by 26% atop statins. It outperformed bempedoic acid/eze combinations and was safe.
How does enlicitide compare to other non-statin therapies?
In ACC.26 comparisons, enlicitide bested other add-ons for LDL lowering. It offers an oral adherence alternative matching injectables, expanding options for primary/secondary prevention per 2026 tiers.
What is the regulatory and trial status of enlicitide?
Fast-track FDA review expected fall 2026, with CVOTs enrolling. Ties to inclisiran real-world data reinforce its potential in lipid management.
Merck CORALreef AddOn ph3 ACC.26: 65% LDL drop/81% <70/78% <55/26% Lp(a) vs bempedoic/eze atop statins, safe; ACC.26 quick-take reinforces oral adherence alt matching injectables. Expands LDL options for primary/sec prev per 2026 tiers; fast-track FDA fall '26, CVOTs enrolling. Ties to inclisiran real-world.